API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.globenewswire.com//news-release/2023/10/20/2764004/0/en/Journey-Medical-Corporation-Announces-Data-from-Bioavailability-Study-of-DFD-29-Minocycline-Hydrochloride-Modified-Release-Capsules-40-mg-vs-Solodyn-Minocycline-Hydrochloride-Exten.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-gets-usfda-nod-for-generic-acne-treating-drug/articleshow/101107316.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203553
https://www.globenewswire.com/news-release/2023/06/13/2687130/0/en/Journey-Medical-Corporation-Announces-Positive-Topline-Data-from-Phase-1-Clinical-Trial-Assessing-the-Impact-of-DFD-29-Minocycline-Hydrochloride-Modified-Release-Capsules-40-mg-on-.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214934
https://www.clinicaltrialsarena.com/news/journey-medical-ppr-therapy-trial/
https://www.globenewswire.com/news-release/2023/01/10/2586177/0/en/Journey-Medical-Corporation-Completes-Enrollment-in-Phase-3-Clinical-Trials-Evaluating-DFD-29-Minocycline-Modified-Release-Capsules-40-mg-for-the-Treatment-of-Papulopustular-Rosace.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204394
https://www.globenewswire.com/news-release/2022/08/30/2506755/0/en/Journey-Medical-Corporation-Announces-50-Enrollment-Milestone-Achieved-in-Phase-3-Clinical-Trials-Evaluating-DFD-29-Minocycline-Modified-Release-Capsules-40-mg-for-the-Treatment-of.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214934
https://health.economictimes.indiatimes.com/news/pharma/glenmark-launches-topical-gel-for-treatment-of-moderate-severe-acne/92801284
https://www.pharmacompass.com/pdf/news/fda-confirms-para-iv-patent-litigation-for-minocycline-hydrochloride-aerosol-foam-1649312464.pdf
https://www.globenewswire.com/news-release/2021/10/05/2308650/0/en/VYNE-Therapeutics-Announces-its-China-Partner-s-Enrollment-of-First-Patient-in-Phase-3-Study-of-AMZEEQ-in-Patients-with-Moderate-to-Severe-Acne.html
https://www.globenewswire.com/news-release/2021/01/21/2162077/0/en/VYNE-Therapeutics-Announces-Contract-Execution-for-AMZEEQ-minocycline-and-ZILXI-minocycline-with-Major-Pharmacy-Benefit-Management-PBM-Company.html#:~:text=January%2021%2C%202021%2008%3A00,%7C%20Source%3A%20VYNE%20Therapeutics%20Inc.&text=(Nasdaq%3A%20VYNE)%20(%E2%80%9C,)%20topical%20foam%2C%201.5%25.
https://www.globenewswire.com/news-release/2020/12/15/2145298/0/en/VYNE-Therapeutics-Announces-New-U-S-Patent-Expiring-in-2037-for-AMZEEQ-minocycline-topical-foam-4.html
https://www.pharmacompass.com/pdf/news/fda-confirm-paragraph-iv-patent-certifications-minocin-minocycline-hydrochloride-1609403837.pdf
https://www.globenewswire.com/fr/news-release/2020/12/01/2137415/0/en/VYNE-Therapeutics-Announces-Publication-of-Long-term-Safety-Efficacy-Data-for-ZILXI-minocycline-topical-foam-1-5-in-the-Journal-of-Clinical-and-Aesthetic-Dermatology.html
https://www.prnewswire.com/news-releases/citius-pharmaceuticals-achieves-chemical-manufacturing-and-control-milestones-for-mino-lok-301135361.html
https://www.prnewswire.com/news-releases/therapeutic-solutions-international-reports-synergistic-suppression-of-suicide-associated-neuroinflammatory-pathway-by-quadramune-and-minocycline-301120336.html
https://www.prnewswire.com/news-releases/menlo-therapeutics-receives-fda-approval-of-zilxi-minocycline-topical-foam-1-5-the-first-topical-minocycline-treatment-for-rosacea-301067795.html
https://www.globenewswire.com/news-release/2020/05/27/2039354/0/en/Menlo-Therapeutics-Announces-Covered-Status-for-AMZEEQ-minocycline-topical-foam-4-on-Additional-Commercial-Formulary.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213662
https://www.globenewswire.com/news-release/2020/04/23/2020865/0/en/Menlo-Therapeutics-and-Cutia-Therapeutics-Enter-into-Exclusive-License-Agreement-for-AMZEEQ-and-Approved-Topical-Minocycline-Products-in-Greater-China.html
https://www.globenewswire.com/news-release/2020/04/23/2020976/0/en/Adamis-Pharmaceuticals-Announces-Publication-Demonstrating-PET-Scan-Results-of-Higher-Dose-Naloxone-in-Monkeys.html
https://www.prnewswire.com/news-releases/foamix-announces-amzeeq-minocycline-achievement-of-preferred-status-on-express-scripts-national-preferred-formulary-one-of-the-largest-commercial-formularies-in-the-us-300986316.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204453
https://www.contractpharma.com/contents/view_breaking-news/2019-10-23/foamix-enters-contract-manufacturing-agreement/
https://www.prnewswire.com/news-releases/foamix-receives-fda-approval-of-amzeeq-topical-minocycline-treatment-for-millions-of-moderate-to-severe-acne-sufferers-300941412.html
https://www.prnewswire.com/news-releases/foamix-announces-fda-acceptance-of-its-new-drug-application-for-fmx103-minocycline-foam-for-the-treatment-of-moderate-to-severe-papulopustular-rosacea-300940656.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-2-2019-1570003052.pdf
https://www.prnewswire.com/news-releases/hovione-announces-successful-end-of-phase-2-meeting-with-the-fda-and-outlines-phase-3-program-for-minocycline-topical-gel-300922397.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203443
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202261
https://health.economictimes.indiatimes.com/news/pharma/zydus-cadilas-acne-drug-receives-usfda-go-ahead/70495524
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201467
http://www.pharmatimes.com/news/nhs_england_scraps_7_more_drugs_on_prescription_1293506
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203443
https://www.reuters.com/article/us-foamix-fda/foamixs-treatment-for-common-skin-condition-meets-late-stage-trial-goals-idUSKCN1NC1ES
https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html
https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html
https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html
https://www.prnewswire.com/news-releases/biopharmx-initiates-phase-2b-trial-of-bpx-04-for-rosacea-300729730.html
https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202261
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-closing-underwritten-public
https://www.prnewswire.com/news-releases/us-patent-and-trademark-office-awards-biopharmx-patent-protection-for-novel-tetracycline-class-topical-drug-compositions-300615514.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204453
https://www.reuters.com/article/us-impax-labs-lawsuit/impax-broke-u-s-antitrust-law-by-delaying-generic-drug-jury-told-idUSKCN1GO1XZ
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-highlight-commitment-antibiotics-and